🔎 Trials Near Me

Home › Refractory Anemia na May Sobrang Blasts › Texas

Pag-aaral pangklinika para sa Refractory Anemia na May Sobrang Blasts sa Texas

7 pag-aaral para sa Refractory Anemia na May Sobrang Blasts ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT00801489

Luspatercept + Darbepoetin in MDS

  • Harold C. Simmons Comprehensive Cancer Center of UT Southwestern, Dallas
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07096297

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03383575

Personalized NK Cell Therapy in CBT

  • M D Anderson Cancer Center, Houston
Nagre-recruitPhase 2
Edad 15 hanggang 80 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT02727803

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • University of Texas Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • MD Anderson, Houston
Nagre-recruitPhase 2
Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

  • MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT06680752

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.